WO2001044455A3 - Antisense oligonucleotides for the inhibition of expression of type i procollagen - Google Patents

Antisense oligonucleotides for the inhibition of expression of type i procollagen Download PDF

Info

Publication number
WO2001044455A3
WO2001044455A3 PCT/GB2000/004741 GB0004741W WO0144455A3 WO 2001044455 A3 WO2001044455 A3 WO 2001044455A3 GB 0004741 W GB0004741 W GB 0004741W WO 0144455 A3 WO0144455 A3 WO 0144455A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
procollagen
inhibition
type
antisense oligonucleotides
Prior art date
Application number
PCT/GB2000/004741
Other languages
French (fr)
Other versions
WO2001044455A2 (en
Inventor
Rajinder Beri
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Rajinder Beri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU25297/01A priority Critical patent/AU2529701A/en
Priority to AT00988966T priority patent/ATE309338T1/en
Priority to CA002390674A priority patent/CA2390674A1/en
Priority to US10/149,352 priority patent/US7173122B2/en
Priority to EP00988966A priority patent/EP1244781B1/en
Priority to JP2001545532A priority patent/JP2003516752A/en
Priority to KR1020027007591A priority patent/KR20020064936A/en
Priority to MXPA02005871A priority patent/MXPA02005871A/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Rajinder Beri filed Critical Astrazeneca Ab
Priority to BR0016347-3A priority patent/BR0016347A/en
Priority to IL14964000A priority patent/IL149640A0/en
Priority to NZ519008A priority patent/NZ519008A/en
Priority to DE60023943T priority patent/DE60023943T2/en
Publication of WO2001044455A2 publication Critical patent/WO2001044455A2/en
Publication of WO2001044455A3 publication Critical patent/WO2001044455A3/en
Priority to NO20022799A priority patent/NO20022799L/en
Priority to US11/021,603 priority patent/US7396823B2/en
Priority to US11/521,843 priority patent/US8173612B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene.
PCT/GB2000/004741 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen WO2001044455A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR0016347-3A BR0016347A (en) 1999-12-15 2000-12-12 Antisense oligonucleotides
AT00988966T ATE309338T1 (en) 1999-12-15 2000-12-12 ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF EXPRESSION OF TYPE I PROCOLLAGEN
IL14964000A IL149640A0 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides
EP00988966A EP1244781B1 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for inhibiting the expression of type i procollagen
JP2001545532A JP2003516752A (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for inhibiting the expression of type I procollagen
KR1020027007591A KR20020064936A (en) 1999-12-15 2000-12-12 Antisense Oligonucleotides for the Inhibition of Expression of Type I Procollagen
MXPA02005871A MXPA02005871A (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen.
AU25297/01A AU2529701A (en) 1999-12-15 2000-12-12 Antisense oligonucleotides
CA002390674A CA2390674A1 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen
US10/149,352 US7173122B2 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides to type I procollagen
NZ519008A NZ519008A (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type I procollagen
DE60023943T DE60023943T2 (en) 1999-12-15 2000-12-12 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF THE EXPRESSION OF TYPE I PROCOLLAGEN
NO20022799A NO20022799L (en) 1999-12-15 2002-06-12 Antigen oligonucleotides
US11/021,603 US7396823B2 (en) 1999-12-15 2004-12-21 Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
US11/521,843 US8173612B2 (en) 1999-12-15 2006-09-15 Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929487.8A GB9929487D0 (en) 1999-12-15 1999-12-15 Antisense oligonucleotides
GB9929487.8 1999-12-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10149352 A-371-Of-International 2000-12-12
US11/021,603 Continuation-In-Part US7396823B2 (en) 1999-12-15 2004-12-21 Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis

Publications (2)

Publication Number Publication Date
WO2001044455A2 WO2001044455A2 (en) 2001-06-21
WO2001044455A3 true WO2001044455A3 (en) 2002-01-10

Family

ID=10866254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004741 WO2001044455A2 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen

Country Status (17)

Country Link
US (1) US7173122B2 (en)
EP (3) EP2025752A3 (en)
JP (1) JP2003516752A (en)
KR (1) KR20020064936A (en)
CN (1) CN1423695A (en)
AT (2) ATE410510T1 (en)
AU (1) AU2529701A (en)
BR (1) BR0016347A (en)
CA (1) CA2390674A1 (en)
DE (2) DE60023943T2 (en)
GB (1) GB9929487D0 (en)
IL (1) IL149640A0 (en)
MX (1) MXPA02005871A (en)
NO (1) NO20022799L (en)
NZ (1) NZ519008A (en)
WO (1) WO2001044455A2 (en)
ZA (1) ZA200203878B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396823B2 (en) * 1999-12-15 2008-07-08 Nath Rahul K Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
CN111378657B (en) * 2018-12-28 2024-03-15 苏州瑞博生物技术股份有限公司 siRNA for inhibiting COL1A1 gene expression, pharmaceutical composition containing siRNA and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011149A1 (en) * 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
WO1994022487A1 (en) * 1993-03-26 1994-10-13 Thomas Jefferson University Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
DE19508923A1 (en) * 1995-03-13 1996-09-19 Hoechst Ag New oligo:nucleotide analogues contg. phospho:mono:ester bridges
WO1998033904A2 (en) * 1997-01-31 1998-08-06 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH An antisense oligonucleotide preparation method
WO1999049065A1 (en) * 1998-03-26 1999-09-30 Isis Pharmaceuticals, Inc. Antisense modulation of human mdm2 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
PT739898E (en) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh PHOSPHONUCLETIC ACID MONO-ESTERS PROCESS FOR PREPARING AND USING
EP0736608A1 (en) * 1995-04-08 1996-10-09 Roche Diagnostics GmbH Method for the specific amplification and the detection of DNA or RNA
CA2399371A1 (en) * 1999-11-12 2001-05-17 Fibrogen, Inc. Animal collagens and gelatins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011149A1 (en) * 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
WO1994022487A1 (en) * 1993-03-26 1994-10-13 Thomas Jefferson University Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
DE19508923A1 (en) * 1995-03-13 1996-09-19 Hoechst Ag New oligo:nucleotide analogues contg. phospho:mono:ester bridges
WO1998033904A2 (en) * 1997-01-31 1998-08-06 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH An antisense oligonucleotide preparation method
WO1999049065A1 (en) * 1998-03-26 1999-09-30 Isis Pharmaceuticals, Inc. Antisense modulation of human mdm2 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALTMANN K -H ET AL: "NOVEL CHEMISTRY", NEW YORK, WILEY-LISS,US, 1998, pages 73 - 107, XP002119324, ISBN: 0-471-17279-0 *
AUSSERLECHNER MICHAEL J ET AL: "Altered procollagen mRNA expression during the progression of avian scleroderma.", MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10-01), pages 654 - 662, XP000986380, ISSN: 1076-1551 *
COLIGE A ET AL: "USE OF AN ANTISENSE OLIGONUCLEOTIDE TO INHIBIT EXPRESSION OF A MUTATED HUMAN PROCOLLAGEN GENE (COL1A1) IN TRANSFECTED MOUSE 3T3 CELLS", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 32, no. 1, 12 January 1993 (1993-01-12), pages 7 - 11, XP000652779, ISSN: 0006-2960 *
HAWKINS J R ET AL: "A 9-BASE PAIR DELETION IN COL1A1 IN A LETHAL VARIANT OF OSTEOGENESIS IMPERFECTA", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 33, 1991, pages 22370 - 22374, XP000942166, ISSN: 0021-9258 *
KHILLAN JASPAL S ET AL: "Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 14, 1994, 1994, pages 6298 - 6302, XP000942172, ISSN: 0027-8424 *
LAPTEV ALEXEY V ET AL: "Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA.", BIOCHEMISTRY, vol. 33, no. 36, 1994, pages 11033 - 11039, XP000984496, ISSN: 0006-2960 *
ONODA KEISUKE ET AL: "Role of extracellular matrix in experimental vasospasm: Inhibitory effect of antisense oligonucleotide on collagen induction.", STROKE, vol. 27, no. 11, 1996, pages 2102 - 2108, XP000984053, ISSN: 0039-2499 *
PROCKOP D J ET AL: "MUTATIONS IN TYPE 1 PROCOLLAGEN THAT CAUSE OSTEOGENESIS IMPERFECTA:EFFECTS OF THE MUTATIONS ON THE ASSEMBLY OF COLLAGEN INTO FIBRILS, THE BASIS OF PHENOTYPIC VARIATIONS, AND POTENTIAL ANTISESE THERAPIES", JOURNAL OF BONE AND MINERAL RESEARCH,US,NEW YORK, NY, vol. 8, no. SUPPL. 02, 1 December 1993 (1993-12-01), pages 489 - 492, XP000674592, ISSN: 0884-0431 *
RIRIE SETH S ET AL: "An RNA oligonucleotide corresponding to the polypyrimidine region of the rat alpha1(I) procollagen promoter forms a stable triplex and inhibits transcription.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 249, no. 1, 10 August 1998 (1998-08-10), pages 218 - 221, XP000942267, ISSN: 0006-291X *
UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE", CHEMICAL REVIEWS,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543 - 584, XP000141412, ISSN: 0009-2665 *

Also Published As

Publication number Publication date
US7173122B2 (en) 2007-02-06
WO2001044455A2 (en) 2001-06-21
NO20022799D0 (en) 2002-06-12
IL149640A0 (en) 2002-11-10
EP1698695A2 (en) 2006-09-06
GB9929487D0 (en) 2000-02-09
CN1423695A (en) 2003-06-11
DE60023943D1 (en) 2005-12-15
EP1698695A3 (en) 2007-02-14
JP2003516752A (en) 2003-05-20
AU2529701A (en) 2001-06-25
EP2025752A3 (en) 2009-08-12
CA2390674A1 (en) 2001-06-21
US20030105050A1 (en) 2003-06-05
ATE410510T1 (en) 2008-10-15
EP1244781B1 (en) 2005-11-09
EP1698695B1 (en) 2008-10-08
ZA200203878B (en) 2003-08-15
DE60023943T2 (en) 2006-08-03
ATE309338T1 (en) 2005-11-15
KR20020064936A (en) 2002-08-10
MXPA02005871A (en) 2002-10-23
BR0016347A (en) 2002-09-10
DE60040495D1 (en) 2008-11-20
NZ519008A (en) 2004-04-30
NO20022799L (en) 2002-06-12
EP2025752A2 (en) 2009-02-18
EP1244781A2 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
AU2002345089A1 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
ZA200006594B (en) DSRNA-mediated regulation of gene expression in plants.
EE200000522A (en) Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity
ZA200109901B (en) Method for down-regulating GDF-8 activity.
HK1048337A1 (en) Oligonucleotides for inhibiting the expression of human eg5.
WO2000017233A3 (en) Genes of the 1-desoxy-d-xylulose biosynthetic pathway
WO2001048183A3 (en) Improvements relating to double-stranded rna inhibition
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
AU2001294842A1 (en) A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
EP1849868A3 (en) Plant defensins
PL346162A1 (en) Antisense oligonucleotides for the inhibition of vegf expression
WO2001044455A3 (en) Antisense oligonucleotides for the inhibition of expression of type i procollagen
IL131433A0 (en) Biosynthesis genes from actinoplanes sp.
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
AU2001278509A1 (en) Nucleotide sequences which code for the atr43 gene
AU2002211615A1 (en) Genetic insulator for preventing influence by another gene promoter
EP1086116A4 (en) Compositions and methods for the pulmonary delivery of nucleic acids
AU2001293808A1 (en) Nucleotide sequences which code for the atr61 gene
AU2001291658A1 (en) Nucleotide sequences which code for the ccpa2 gene
AU2001293730A1 (en) Nucleotide sequences which code for the chra gene
AU2001295445A1 (en) Nucleotide sequences which code for the mike17 gene
AU2001295470A1 (en) Nucleotide sequences which code for the gpmb gene
AU2001285947A1 (en) Nucleotide sequences which code for the ndka gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149640

Country of ref document: IL

Ref document number: 25297/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200203878

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 519008

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000988966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2390674

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10149352

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 545532

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005871

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027007591

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 00817282X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027007591

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000988966

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 519008

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519008

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2000988966

Country of ref document: EP